Unraveling the genetic underpinnings of myeloproliferative neoplasms and understanding their effect on disease course and response to therapy: Proceedings from the 6th international post-ASH symposium

American Journal of Hematology

Volumn 87, Issue 5, 2012, Pages 562-568

  Abdel Wahab, Omar ^a   Pardanani, Animesh ^b   Bernard, Olivier A ^c   Finazzi, Guido ^d   Crispino, John D ^e   Gisslinger, Heinz ^f   Kralovics, Robert ^f   Odenike, Olatoyosi ^g   Bhalla, Kapil ^h   Gupta, Vikas ⁱ   Barosi, Giovanni ^j   Gotlib, Jason ^k   Guglielmelli, Paola ^l   Kiladjian, Jean Jacques ^m   Noel, Pierre ⁿ   Cazzola, Mario ^o   Vannucchi, Alessandro M ^l   Hoffman, Ronald ^p   Barbui, Tiziano ^d   Thiele, Juergen ^q,r   Van Etten, Richard A ^s   Mughal, Tariq ^f   Tefferi, Ayalew ^b   more..

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b MAYO CLINIC   (United States)

^c INSTITUT GUSTAVE ROUSSY   (France)

^d OSPEDALI RIUNITI   (Italy)

^e NORTHWESTERN UNIVERSITY   (United States)

^f MEDICAL UNIVERSITY OF VIENNA   (Austria)

^g UNIVERSITY OF CHICAGO   (United States)

^h UNIVERSITY OF KANSAS CANCER CENTER   (United States)

ⁱ PRINCESS MARGARET HOSPITAL   (Canada)

^j FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^k STANFORD CANCER INSTITUTE   (United States)

^l UNIVERSITY OF FLORENCE   (Italy)

^m SAINT LOUIS HOSPITAL   (France)

ⁿ MAYO CLINIC   (United States)

^o UNIVERSITY OF PAVIA   (Italy)

^p MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^q UNIVERSITY OF COLOGNE   (Germany)

^r Tufts Medical Center ^*

^s TUFTS MEDICAL CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CYT 387; DNA METHYLTRANSFERASE 3A; GIVINOSTAT; HEAT SHOCK PROTEIN 90 INHIBITOR; HYDROXYUREA; JANUS KINASE 2; METHOTREXATE; NUCLEIC ACID BINDING PROTEIN; PACRITINIB; PANOBINOSTAT; PEGINTERFERON ALPHA2A; POMALIDOMIDE; PROTEIN TET2; PROTEIN TYROSINE KINASE INHIBITOR; RUXOLITINIB; SAR 302503; SB 1518; STAT5 PROTEIN; TACROLIMUS; TG 101348; TRANSCRIPTION FACTOR EZH2; UNCLASSIFIED DRUG;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; CHRONIC MYELOID LEUKEMIA; DISEASE COURSE; DNA METHYLATION; DRUG EFFICACY; GENE EXPRESSION; GENE MUTATION; GRAFT VERSUS HOST REACTION; HEMATOPOIESIS; HUMAN; LONG TERM CARE; MORTALITY; MYELOID METAPLASIA; NONHUMAN; OVERALL SURVIVAL; PATHOGENESIS; PHENOTYPE; POLYCYTHEMIA VERA; PRIORITY JOURNAL; PROPHYLAXIS; QUALITY OF LIFE; SIGNAL TRANSDUCTION; SPLEEN SIZE; THROMBOCYTHEMIA; THROMBOCYTOPENIA;

CLINICAL TRIALS AS TOPIC; DISEASE PROGRESSION; DNA METHYLATION; DNA, NEOPLASM; DRUGS, INVESTIGATIONAL; GENES, NEOPLASM; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMATOPOIETIC STEM CELLS; HISTONE DEACETYLASE INHIBITORS; HUMANS; INFLAMMATION; INTERFERON-ALPHA; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MULTICENTER STUDIES AS TOPIC; MYELOPROLIFERATIVE DISORDERS; NEOPLASM PROTEINS; POLYETHYLENE GLYCOLS; PROGNOSIS; RECOMBINANT PROTEINS; THALIDOMIDE; TREATMENT OUTCOME;

EID: 84859905706     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.23169     Document Type: Article

References (75)

1. Pikman Y, Lee BH, Mercher T, et al. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med 2006; 3: e270.
2. Grand FH, Hidalgo-Curtis CE, Ernst T, et al. Frequent CBL mutations associated with 11q acquired uniparental disomy in myeloproliferative neoplasms. Blood 2009; 113: 6182-6192.
3. Oh ST, Simonds EF, Jones C, et al. Novel mutations in the inhibitory adaptor protein LNK drive JAK-STAT signaling in patients with myeloproliferative neoplasms. Blood 2010; 116: 988-992.
4. Pardanani A, Lasho T, Finke C, et al. LNK mutation studies in blast-phase myeloproliferative neoplasms, and in chronic-phase disease with TET2, IDH, JAK2 or MPL mutations. Leukemia 2010; 24: 1713-1718.
5. Delhommeau F, Dupont S, Della Valle V, et al. Mutation in TET2 in myeloid cancers. N Engl J Med 2009; 360: 2289-2301.
6. Tefferi A, Pardanani A, Lim KH, et al. TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis. Leukemia 2009; 23: 905-911.
7. Abdel-Wahab O, Pardanani A, Rampal R, et al. DNMT3A mutational analysis in primary myelofibrosis, chronic myelomonocytic leukemia and advanced phases of myeloproliferative neoplasms. Leukemia 2011; 25: 1219-1220.
8. Stegelmann F, Bullinger L, Schlenk RF, et al. DNMT3A mutations in myeloproliferative neoplasms. Leukemia 2011; 25: 1217-1219.
9. Ernst T, Chase AJ, Score J, et al. Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders. Nat Genet 2010; 42: 722-726.
10. Brecqueville M, Cervera N, Adélaïde J, et al. Mutations and deletions of the SUZ12 polycomb gene in myeloproliferative neoplasms. Blood Cancer J 2011; 1: e33.
11. Score J, Hidalgo-Curtis C, Jones AV, et al. Inactivation of polycomb repressive complex 2 components in myeloproliferative and myelodysplastic/myeloproliferative neoplasms. Blood 2011; 119: 1208-1213.
12. Puda A, Milosevic JD, Berg T, et al. Frequent deletions of JARID2 in leukemic transformation of chronic myeloid malignancies. Am J Hematol 2011; 87: 245-250.
13. Verstovsek S, Mesa RA, Gotlib J, et al. Consistent benefit of ruxolitinib over placebo in spleen volume reduction and symptom improvement across subgroups and overall survival advantage: Results from COMFORT-I (Abstract 278). Blood 2011; 118.
14. Harrison C, Kiladjian J-J, Gisslinger H, et al. Ruxolitinib provides reductions in splenomegaly across subgroups: An analysis of spleen response in the COMFORT-II study (Abstract 279). Blood 2011; 118.
15. Pardanani A, Gotlib J, Jamieson C, et al. SAR302503: Interim safety, efficacy and long-term impact on JAK2 V617F allele burden in a phase I/II study in patients with myelofibrosis (Abstract 3838). Blood 2011; 118.
16. Pardanani A, Gotlib J, Gupta V, et al. An expanded multicenter phase I/II study of CYT387, a JAK-1/2 inhibitor for the treatment of myelofibrosis (Abstract 3849). Blood 2011; 118.
17. Komrokji R, Wadleigh M, Seymour JF, et al. Results of a phase 2 study of Pacritinib (SB1518), a novel oral JAK2 inhibitor, in patients with primary, postpolycythemia vera, and postessential thrombocythemia myelofibrosis (Abstract 282). Blood 2011; 118.
18. Mascarenhas J, Mercado A, Rodriguez A, et al. Prolonged low dose therapy with a pan-deacetylase inhibtor, panobinostat (LBH589), in patients with myelofibrosis (Abstract 794). Blood 2011; 118.
19. Rambaldi A, Finazzi G, Vannucchi AM, et al. A phase II study of the HDAC inhibitor givinostat in combination with hydroxyurea in patients with polycythemia vera resistant to hydroxyurea monotherapy (Abstract 1748). Blood 2011; 118.
20. Turlure P, Cambier N, Roussel M, et al. Complete hematological, molecular and histological remissions without cytoreductive treatment lasting after pegylated-interferon α-2a (peg-IFNα-2a) therapy in polycythemia vera (PV): Long term results of a phase 2 trial (Abstract 280). Blood 2011; 118.
21. Begna K, Pardanani A, Mesa RA, et al. Pomalidomide therapy for myelofibrosis: Analysis of results from three consecutive clinical trials (Abstract 1759). Blood 2011; 118.
22. Shastri A, Kadia T, Cortes JE, et al. Phase II study of low-dose pomalidomide in patients with myelofibrosis and significant anemia (hemoglobin <10 g/dL) (Abstract 1757). Blood 2011; 118.
23. Rondelli D, Goldberg JD, Marchioli R, et al. Results of phase II clinical trial MPD-RC 101: Allogeneic hematopoietic stem cell transplantation conditioned with fludarabine/melphalan in patients with myelofibrosis (Abstract 1750). Blood 2011; 118.
24. Abdel-Wahab O, Mullally A, Hedvat C, et al. Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies. Blood 2009; 114: 144-147.
25. Ko M, Bandukwala HS, An J, et al. Ten-eleven-translocation 2 (TET2) negatively regulates homeostasis and differentiation of hematopoietic stem cells in mice. Proc Natl Acad Sci USA 2011; 108: 14566-14571.
26. Li Z, Cai X, Cai C, et al. Deletion of Tet2 in mice leads to dysregulated hematopoietic stem cells and subsequent development of myeloid malignancies. Blood 2011; 118: 4509-4518.
27. Moran-Crusio K, Reavie L, Shih A, et al. Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation. Cancer Cell 2011; 20: 11-24.
28. Quivoron C, Couronne L, Della Valle V, et al. TET2 inactivation results in pleiotropic hematopoietic abnormalities in mouse and is a recurrent event during human lymphomagenesis. Cancer Cell 2011; 20: 25-38.
29. Pronier E, Almire C, Mokrani H, et al. Inhibition of TET2-mediated conversion of 5-methylcytosine to 5-hydroxymethylcytosine disturbs erythroid and granulomonocytic differentiation of human hematopoietic progenitors. Blood 2011; 118: 2551-2555.
30. Ko M, Huang Y, Jankowska AM, et al. Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2. Nature 2010; 468: 839-843.
31. Pastor WA, Pape UJ, Huang Y, et al. Genome-wide mapping of 5-hydroxymethylcytosine in embryonic stem cells. Nature 2011; 473: 394-397.
32. Wu H, D'Alessio AC, Ito S, et al. Genome-wide analysis of 5-hydroxymethylcytosine distribution reveals its dual function in transcriptional regulation in mouse embryonic stem cells. Genes Dev 2011; 25: 679-684.
33. Valinluck V, Sowers LC. Endogenous cytosine damage products alter the site selectivity of human DNA maintenance methyltransferase DNMT1. Cancer Res 2007; 67: 946-950.
34. Boorstein RJ, Cummings AJr, Marenstein DR, et al. Definitive identification of mammalian 5-hydroxymethyluracil DNA N-glycosylase activity as SMUG1. J Biol Chem 2001; 276: 41991-41997.
35. Bennett MT, Rodgers MT, Hebert AS, et al. Specificity of human thymine DNA glycosylase depends on N-glycosidic bond stability. J Am Chem Soc 2006; 128: 12510-12519.
36. He YF, Li BZ, Li Z, et al. Tet-mediated formation of 5-carboxylcytosine and its excision by TDG in mammalian DNA. Science 2011; 333: 1303-1307.
37. Figueroa ME, Abdel-Wahab O, Lu C, et al. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell 2010; 18: 553-567.
38. Abdel-Wahab O, Manshouri T, Patel J, et al. Genetic analysis of transforming events that convert chronic myeloproliferative neoplasms to leukemias. Cancer Res 2010; 70: 447-452.
39. Mullally A, Poveromo L, Brumme K, et al. Evaluating clonal dominance in a murine knock-in model of Jak2V617F MPN (Abstract). Blood 2011; 118.
40. Tadokoro Y, Ema H, Okano M, et al. De novo DNA methyltransferase is essential for self-renewal, but not for differentiation, in hematopoietic stem cells. J Exp Med 2007; 204: 715-722.
41. Challen GA, Sun D, Jeong M, et al. Dnmt3a is essential for hematopoietic stem cell differentiation. Nat Genet 2011; 44: 23-31.
42. Abdel-Wahab O, Pardanani A, Patel J, et al. Concomitant analysis of EZH2 and ASXL1 mutations in myelofibrosis, chronic myelomonocytic leukemia and blast-phase myeloproliferative neoplasms. Leukemia 2011; 25: 1200-1202.
43. Ernst T, Chase AJ, Score J, et al. Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders. Nat Genet 2010; 42: 722-726.
44. Guglielmelli P, Biamonte F, Score J, et al. EZH2 mutational status predicts poor survival in myelofibrosis. Blood 2011; 118: 5227-5234.
45. Su IH, Basavaraj A, Krutchinsky AN, et al. Ezh2 controls B cell development through histone H3 methylation and Igh rearrangement. Nat Immunol 2003; 4: 124-131.
46. Herrera-Merchan A, Arranz L, Ligos JM, et al. Ectopic expression of the histone methyltransferase Ezh2 in haematopoietic stem cells causes myeloproliferative disease. Nat Commun 2012; 3: 623.
47. Hornakova T, Springuel L, Devreux J, et al. Oncogenic JAK1 and JAK2-activating mutations resistant to ATP-competitive inhibitors. Hematologica 2011; 96: 845-853.
48. Demoulin JB, Uyttenhove C, Lejeune D, et al. STAT5 activation is required for interleukin-9-dependent growth and transformation of lymphoid cells. Cancer Res 2000; 60: 3971-3977.
49. Deshpande A, Reddy MM, Schade GO, et al. Kinase domain mutations confer resistance to novel inhibitors targeting JAK2V617F in myeloproliferative neoplasms. Leukemia 2011 [e-pub ahead of print].
50. Fiskus W, Verstovsek S, Manshouri T, et al. Heat shock protein 90 inhibitor is synergistic with JAK2 inhibitor and overcomes resistance to JAK2-TKI in human myeloproliferative neoplasm cells. Clin Cancer Res 2011; 17: 7347-7358.
51. Barosi G, Viarengo G, Pecci A, et al. Diagnostic and clinical relevance of the number of circulating CD34(+) cells in myelofibrosis with myeloid metaplasia. Blood 2001; 98: 3249-3255.
52. Massa M, Rosti V, Ramajoli I, et al. Circulating CD34+, CD133+, and vascular endothelial growth factor receptor 2-positive endothelial progenitor cells in myelofibrosis with myeloid metaplasia. J Clin Oncol 2005; 23: 5688-5695.
53. Wang X, Prakash S, Lu M, et al. Characterization of Splenic CD34+ cells from patients with primary myelofibrosis (Abstract 2810). Blood 2011; 118.
54. Verstovsek S, Kantarjian H, Mesa RA, et al. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med 2010; 363: 1117-1127.
55. Koppikar P, Abdel-Wahab O, Hedvat C, et al. Efficacy of the JAK2 inhibitor INCB16562 in a murine model of MPLW515L-induced thrombocytosis and myelofibrosis. Blood 2010; 115: 2919-2927.
56. Tefferi A, Vaidya R, Caramazza D, et al. Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: A comprehensive cytokine profiling study. J Clin Oncol 2011; 29: 1356-1363.
57. Pardanani A, Begna K, Finke C, et al. Circulating levels of MCP-1, sIL-2R, IL-15, and IL-8 predict anemia response to pomalidomide therapy in myelofibrosis. Am J Hematol 2011; 86: 343-345.
58. Mullally A, Lane SW, Ball B, et al. Physiological Jak2V617F expression causes a lethal myeloproliferative neoplasm with differential effects on hematopoietic stem and progenitor cells. Cancer Cell 2010; 17: 584-596.
59. Pardanani A, Vannucchi AM, Passamonti F, et al. JAK inhibitor therapy for myelofibrosis: Critical assessment of value and limitations. Leukemia 2011; 25: 218-225.
60. Yan D, Hutchison RE, Mohi G. Critical requirement for Stat5 in a mouse model of polycythemia vera. Blood 2011 [e-pub ahead of print].
61. Walz C, Ahmed W, Lazarides K, et al. Essential role for Stat5a/b in myeloproliferative neoplasms induced by BCR-ABL1 and Jak2V617F in mice. Blood 2012 [e-pub ahead of print].
62. Tiedt R, Hao-Shen H, Sobas MA, et al. Ratio of mutant JAK2-V617F to wild-type Jak2 determines the MPD phenotypes in transgenic mice. Blood 2008; 111: 3931-3940.
63. Chen E, Beer PA, Godfrey AL, et al. Distinct clinical phenotypes associated with JAK2V617F reflect differential STAT1 signaling. Cancer Cell 2010; 18: 524-535.
64. Passamonti F, Cervantes F, Vannucchi AM, et al. A dynamic prognostic model to predict survival in primary myelofibrosis: A study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). Blood 2010; 115: 1703-1708.
65. Gangat N, Caramazza D, Vaidya R, et al. DIPSS plus: A refined dynamic international prognostic scoring system for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. J Clin Oncol 2011; 29: 392-397.
66. Tefferi A, Jimma T, Gangat N, et al. Predictors of greater than 80% 2-year mortality in primary myelofibrosis: A Mayo Clinic study of 884 karyotypically annotated patients. Blood 2011; 118: 4595-4598.
67. Tefferi A, Rumi E, Finazzi G, et al. Survival and prognosis among 1, 263 patients with polycythemia vera: An international study (Abstract 277). Blood 2011; 118.
68. Pardanani A, Gotlib JR, Jamieson C, et al. Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis. J Clin Oncol 2011; 29: 789-796.
69. Tefferi A, Litzow MR, Pardanani A. Long-term outcome of treatment with ruxolitinib in myelofibrosis. N Engl J Med 2011; 365: 1455-1457.
70. Verstovsek S, Kantarjian HM, Estrov Z, et al. Comparison of outcomes of advanced myelofibrosis patients treated with Ruxolitinib (INCB018424) to those of a historical control group: Survival advantage of Ruxolitinib therapy (Abstract 793). Blood 2011; 118.
71. Verstovsek S, Estrov A, Cortes JE, et al. The MD Anderson cancer center (MDACC) experience with Ruxolitinib, an oral JAK1 and JAK2 inhibitor, in myelofibrosis: Long-term Follow-up outcomes of 107 patients from a phase I/II study (Abstract 3851). Blood 2011; 118.
72. Kiladjian JJ, Masse A, Cassinat B, et al. Clonal analysis of erythroid progenitors suggests that pegylated interferon alpha-2a treatment targets JAK2V617F clones without affecting TET2 mutant cells. Leukemia 2010; 24: 1519-1523.
73. Quintas-Cardama A, Abdel-Wahab O, Levine RL, et al. Dynamics of mutant alleles in patients with advanced essential thrombocythemia (ET) or polycythemia (PV) during pegylated interferon-Alfa-2A (PEG-IFN-α-2A; Pegasys) therapy (Abstract 281). Blood 2011; 118.
74. Begna KH, Pardanani A, Mesa R, et al. Long-term outcome of pomalidomide therapy in myelofibrosis. Am J Hematol 2012; 87: 66-68.
75. DeAngelo DJTA, Fiskus W, Mesa RA, et al. A phase II trial of panobinostat, an orally available deacetylase inhibitor (DACi), in patients with primary myelofibrosis (PMF), postessential thrombocythemia (ET), and postpolycythemia vera (PV) myelofibrosis (Abstract 630). Blood 2010; 116.